Peripheral Blood Mononuclear Cell DNA 6-Thioguanine Metabolite Levels Correlate with Decreased Interferon-γ Production in Patients with Crohn's Disease on AZA Therapy

Digestive Diseases and Sciences

Volumn 49, Issue 1, 2004, Pages 133-137

  Cuffari, C ^a,b   Li, D Y ^a   Mahoney, J ^a   Barnes, Y ^a   Bayless, T M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS CHILDREN S CENTER   (United States)

Author keywords

6 Mercaptopurine; Azathioprine; Crohn's disease; IL 10; INF ; Lymphocyte DNA 6 TG

Indexed keywords

AZATHIOPRINE; CELL DNA; DNA; DRUG METABOLITE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; MESALAZINE; TIOGUANINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; METABOLISM; MONONUCLEAR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TREATMENT OUTCOME; ULTRAVIOLET RADIATION;

AZATHIOPRINE; CROHN DISEASE; DNA; ERYTHROCYTES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; THIOGUANINE; TREATMENT OUTCOME;

EID: 0842291670     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DDAS.0000011614.88494.ee     Document Type: Article

References (30)

1. Pearson DC, May GR, Fick GH, Sutherland LR: Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med 122:132-142, 1995
2. O'Brien JJ, Bayless TM, Bayless JA: Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology 101:39-46, 1991
3. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, Buschenfelde KHMZ: Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 105:367-372, 1993
4. Present DH, Korelitz BI, Wisch N: Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 302:981-987, 1989
5. Elion GB: The pharmacology of azathioprine. Ann NY Acad Sci 21:401-407, 1977
6. Fairchild CR, Maybaum J, Kennedy KA: Concurrent unilateral chromatid damage and DNA strand breaks in response to 6-thioguanine treatment. Biochem Pharmacol 35:3533-3541, 1986
7. Christie NT, Drake S, Meyn RE: 6-Thioguanine induced DNA damage as a determinant of cytotoxicity in cultured hamster ovary cells. Cancer Res 44:3665-3671, 1986
8. Weinshilboum RN, Sladek SI: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyl transferase activity. Am J Hum Genet 32:651-662, 1980
9. Lennard L: The clinical pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Eur J Clin Pharmacol 43:329-339, 1992
10. Lennard L, Lilleyman JS: Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 7:1816-1823, 1989
11. McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE: Polymorphic thiopurine methyl transferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 85:1897-1902, 1995
12. Evans WE, Homer M, Chu YQ: Altered mercaptopurine metabolism, toxic effects, and dosage requirements in a thiopurine methyl transferase deficient child with acute lymphoblastic leukemia. J Pediatr 119:985-989, 1991
13. Colonna T, Korelitz B: The role of leukopenia in 6-mercaptopurine- induced remission of refractory Crohn's disease. Am J Gastroenterol 89:362-366, 1993
14. Tiede I, Wirtz S, Strand S, Strand D, Atreya R, Mudter J, Hildner K, Holtmann M, Bartsch B, Lehr HA, Blumberg RS, Walczak H, Galle PR, Neurath M: CD28-induced Rac-GTP activiy is the molecular target of azathioprine in primary human CD4+ T-lymphocytes: a mechanism for azathioprine mediated immunosuppression in IBD based on induction of T-cell apoptosis. Gastroenterology 122:A14, 2002
15. Pullman WE, Elsbury S, Kobayashi M, Hapel AJ, Doe WF: Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology 102:529, 1992
16. Nakamura M, Saito H, Kasanuki J, Tamura Y, Yoshida S: Cytokine production in patients with inflammatory bowel disease. Gut 33:933-937, 1992
17. Chomarat P, Rissoan MC, Banchereau J, and Miossec P: Contribution of IL-1, CD14, and CD13 in the increased IL-6 production induced by in vitro monocyte-synoviocyte interactions. J Immunol 155:3645-3652, 1995
18. Hibi T, Ogata H, Sakuraba A: Animal models of inflammatory bowel disease. J Gastroenterol 37:409-417, 2002
19. Kombluth A, Sachar DB, Salomon P: Crohn's disease. In Gastrointestinal Diseases. MH Sleisenger, JS Fordtran (eds). Philadelphia, PA, WB Saunders, 1998, pp 1708-1734
20. Cuffari C, Theoret Y, Latour S, Seidman EG: 6-Mercaptopurine metabolism in Crohn's disease correlation with efficacy and toxicity. Gut 39:401-406, 1996
21. Cuffari C, Seidman EG, Latour S, Theoret Y: Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-maintenance 6-mercaptopurine therapy. Can J Physiol Pharmacol 74:580-585, 1996
22. Lennard L, Rees CA, Lilleyman JS. Childhood leukemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 16:359-363, 1993
23. Dubinsky MC, Feldman E, Abreu MT, Seidman EG, Baroni D, Kornbluth A, Targan SR, Vasiliauskas EA: Idiosyncratic adverse reactions to 6-mercaptopurine and azathioprine can be averted by switching to 6-thioguanine in patients with IBD. Gastroenterology 120:A56, 2001
24. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG: Optimizing and individualizing 6-MP therapy in IBD: The role of 6-MP metabolite levels and TPMT genotyping. Gastroenterology 118:705-713, 2000
25. Paterson ARP, Moriwaki A: Combination chemotherapy: synergistic inhibition of L5178Y ells in culure and in vivo with 6-mercaptopurine and 6-methyl mercapopurine ribonucleotides. Cancer Res 30:2379-2387, 1970
26. Mawatari H, Unei K, Nishimura S, Sakura N, Ueda K: Comparative pharmacokinetics of oral 6-mercaptopurine and intravenous 6-mercaptopurine riboside in children. Pediatr Int 43:673-677, 2001
27. Ansari AR, Marinaki T, Arenas M, Sumi S, Shobowale-Bakre El-M, Lewis K, Woodman I, Duley J, Sanderson J: Mutations in the ITPA gene predicts intolerance to azathioprine. Gastroenterology 124:A11, 2003
28. Hildner K, Marker-Hermann E, Schlaak JF, Becker C, Germann T, Schmitt E, Meyer Zum Buschenfelde KH, Neurath MF: Azathioprine, mycophenolate mofetil, and methotrexate specifically modulate cytokine production by T cells. Ann NY Acad Sci 859:204-207, 1998
29. Van den Berg AP, Twilhaar WN, Corver W, Geerts AB, Mesander G, Klompmaker IJ, Sloof MJH, The TH, de Leij LH: Cyclosporine A is associated with a shift of the TH1/TH2 balance in liver transplant patients. Transplant Proc 30:2378-2379, 1998
30. Durez P, Abramowicz D, Gerard C, Van Mechelen M, Amraoui Z, Dubois C, Leo O, Velu T, Goldman T: In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: Differential modulation by cyclosporin A J Exp Med 177:551-555, 1993